Cell line · CVCL_1609
Papers38
1 to 20 of 38
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. | Cell Stem Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Skeletal progenitors preserve proliferation and self-renewal upon inhibition of mitochondrial respiration by rerouting the TCA cycle. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy. | Front Immunol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Reactive Oxygen Species Rewires Metabolic Activity in Acute Myeloid Leukemia. | Front Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1609/papers